Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma
- PMID: 29475884
- DOI: 10.1158/2159-8290.CD-RW2018-032
Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma
Abstract
Axitinib plus pembrolizumab has a 73% response rate in previously untreated advanced renal cell carcinoma.
©2018 American Association for Cancer Research.
Comment on
-
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10. Lancet Oncol. 2018. PMID: 29439857 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
